Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Scilex Holding Co's share price for the quarter that ended in Mar. 2026 was €3.356276. Scilex Holding Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 7.03 Mil. Therefore, Scilex Holding Co's market cap for the quarter that ended in Mar. 2026 was €23.60 Mil.
Scilex Holding Co's quarterly market cap
stayed the same
from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then
increased
from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€23.60 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Scilex Holding Co's Enterprise Value for Today is €127.61 Mil.
Scilex Holding Co (FRA:D8B0) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Scilex Holding Co Market Cap Related Terms
Scilex Holding Co Market Cap Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:D8B0 vs MIRA, NSRX, MDCX: Market Cap Comparison
For the Drug Manufacturers - General subindustry, Scilex Holding Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Scilex Holding Co's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (FRA:D8B0) has a Market Cap of €48.99 Mil as of Jul. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Scilex Holding Co and its competitors. According to the industry distribution chart, Scilex Holding Co ranks #693 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 67.8%.
Is Scilex Holding Co's Market Cap too high?
Scilex Holding Co's current Market Cap is €48.99 Mil. Based on the distribution chart, Scilex Holding Co ranks #693 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Scilex Holding Co has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's Market Cap compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #693 out of 1022 companies for Market Cap. This places Scilex Holding Co in the lower half of its industry. The industry median Market Cap is 222.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 222.28, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Scilex Holding Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 222.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current Market Cap is €48.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (FRA:D8B0) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.77, compared to a current price of €6.40 — trading 34.2% above its estimated fair value. The current Market Cap is €48.99 Mil. Scilex Holding Co's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Scilex Holding Co (FRA:D8B0), the current Market Cap is €48.99 Mil as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued.
The current stock price of €6.40 is trading 34.2% above its estimated GF Value™ of €4.77.
GuruFocus considers Scilex Holding Co to be Significantly Overvalued.
Key valuation signals for FRA:D8B0:
Market Cap: €48.99 Mil
GF Value™: €4.77 vs. price of €6.40 (34.2% above fair value)
No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
39GF Score
Get the complete analysis for FRA:D8B0
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D8B0 has been successfully added to your 
